Los Angeles Capital Management LLC Lowers Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Los Angeles Capital Management LLC cut its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 57.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 123,714 shares of the company's stock after selling 170,449 shares during the quarter. Los Angeles Capital Management LLC's holdings in Teva Pharmaceutical Industries were worth $1,292,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Harel Insurance Investments & Financial Services Ltd. raised its stake in Teva Pharmaceutical Industries by 184,642.3% during the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 27,711,340 shares of the company's stock valued at $282,656,000 after purchasing an additional 27,696,340 shares during the last quarter. Sound Shore Management Inc CT bought a new stake in shares of Teva Pharmaceutical Industries in the third quarter valued at about $80,791,000. FMR LLC grew its position in Teva Pharmaceutical Industries by 3,553.8% during the third quarter. FMR LLC now owns 2,564,339 shares of the company's stock worth $26,156,000 after buying an additional 2,494,156 shares in the last quarter. Meitav Investment House Ltd. increased its stake in Teva Pharmaceutical Industries by 82.8% during the fourth quarter. Meitav Investment House Ltd. now owns 4,305,674 shares of the company's stock valued at $44,914,000 after acquiring an additional 1,950,500 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. raised its holdings in Teva Pharmaceutical Industries by 6.9% in the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,919,540 shares of the company's stock valued at $301,920,000 after acquiring an additional 1,860,000 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Analyst Ratings Changes

Several research firms recently issued reports on TEVA. Piper Sandler raised shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and increased their price target for the stock from $12.00 to $19.00 in a research report on Monday, February 12th. Jefferies Financial Group raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and boosted their price target for the company from $10.00 to $14.00 in a research note on Tuesday, January 23rd. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from an "underweight" rating to a "neutral" rating and set a $14.00 price objective for the company in a research note on Friday, March 8th. Barclays lifted their price objective on Teva Pharmaceutical Industries from $17.00 to $20.00 and gave the company an "overweight" rating in a report on Thursday. Finally, The Goldman Sachs Group upped their target price on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a "neutral" rating in a report on Monday, February 5th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Teva Pharmaceutical Industries has an average rating of "Moderate Buy" and a consensus target price of $14.11.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Mark Sabag sold 100,000 shares of the company's stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the completion of the transaction, the executive vice president now owns 382,590 shares of the company's stock, valued at approximately $5,172,616.80. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Teva Pharmaceutical Industries news, EVP Mark Sabag sold 100,000 shares of the business's stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the sale, the executive vice president now directly owns 382,590 shares of the company's stock, valued at approximately $5,172,616.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Eric Drape sold 9,815 shares of the firm's stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $13.12, for a total value of $128,772.80. Following the completion of the transaction, the vice president now owns 9,701 shares of the company's stock, valued at approximately $127,277.12. The disclosure for this sale can be found here. In the last 90 days, insiders sold 358,972 shares of company stock worth $4,739,820. Corporate insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Stock Up 1.7 %

Shares of NYSE TEVA traded up $0.27 during mid-day trading on Thursday, reaching $16.01. 16,779,394 shares of the company's stock were exchanged, compared to its average volume of 10,858,707. The company has a current ratio of 1.02, a quick ratio of 0.69 and a debt-to-equity ratio of 2.23. The business has a fifty day simple moving average of $13.75 and a 200 day simple moving average of $11.75. Teva Pharmaceutical Industries Limited has a twelve month low of $7.09 and a twelve month high of $16.25. The firm has a market capitalization of $17.95 billion, a price-to-earnings ratio of -34.06, a PEG ratio of 1.67 and a beta of 1.04.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.